Spatiotemporal T790M Heterogeneity in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0000000000000255
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Mutant‑allele Fraction Heterogeneity Is Associated With Non‑small Cell Lung Cancer Patient Survival

Oncology Letters
Cancer ResearchOncology
2017English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports
MedicineCancer ResearchOncology
2018English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancers
Cancer ResearchOncology
2019English

Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M

Nature Medicine
BiochemistryMedicineGeneticsMolecular Biology
2015English

Primary Concomitant EGFR T790M Mutation Predicted Worse Prognosis in Non-Small Cell Lung Cancer Patients

OncoTargets and Therapy
OncologyPharmacology
2014English

YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

P3.01-95 EGFR Genotype as a Predictor of Survival in EGFR Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy